Last updated on August 2019

Investigate the Safety Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects

Brief description of study

This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF6523 DPI in healthy male subjects first and then in COPD subjects after single or repeated dosesof CHF6523. As an exploratory assessment, the anti-inflammatory effect of CHF6523 in COPDsubjects will be evaluated.

Clinical Study Identifier: NCT04032535

Find a site near you

Start Over

Richmond Pharmacology

London, United Kingdom
  Connect »